Toll free

18002022232

Co - founder, SunAct
Specialist in Blood Cancers & Advanced Cancer Therapies

Dr. Ashay Karpe

Dr. Ashay Karpe, MD, DM, DNB, is a hemato-oncologist with 23 years of experience in cancer care, focusing on hematological malignancies, cellular therapies, and stem cell transplantation. His research has appeared in journals such as the Journal of Global Oncology, South Asian Journal of Cancer, Journal of Clinical Oncology, and eCancer Journal.

He completed his MBBS from KEM Hospital, Mumbai in 2002, followed by an MD in General Medicine from Government Medical College and Hospital, Aurangabad in 2007. He pursued a Fellowship in Clinical Hematology at Tata Medical Centre, Kolkata in 2012, earned a DM and DNB in Medical Oncology from Tata Memorial Hospital, Mumbai in 2016, graduating with a Gold Medal for excellence.

Dr. Karpe continues his practice in hemato-oncology, caring for patients with complex hematological cancers.

He completed his MBBS from KEM Hospital, Mumbai in 2002, followed by an MD in General Medicine from Government Medical College and Hospital, Aurangabad in 2007. He pursued a Fellowship in Clinical Hematology at Tata Medical Centre, Kolkata in 2012, earned a DM and DNB in Medical Oncology from Tata Memorial Hospital, Mumbai in 2016, graduating with a Gold Medal for excellence.

Homi Bhabha National Institute Award – Best Medical Student

Golden AIM Award – Excellence & Leadership in Healthcare (Medical & Haemato-Oncology)

  1. Consensus Statements for Clinical Practice in Advanced/Metastatic Colorectal Cancers in India Using a Modified Delphi Method
  2. Outcomes of selective neck dissection in node positive oral cavity squamous cell carcinoma
  3. Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomes
  4. Re-classifying cT4b buccal mucosa / Gingivo-buccal complex cancers: Do we need to change?
  5. Phase 3 randomized study for evaluation of physician choice Rx versus best supportive care as second-line or beyond therapy in head and neck cancer with poor performance status.
  6. Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).
  7. Real-world experience of checkpoint inhibitors across India: CRSF 2020-01.
  8. Towards a comprehensive head‑and‑neck oncological radiology (HNOR) consortium: Are we there yet?
  9. Role of Selective Neck Dissection in Clinically Single Node Positive Disease in Oral Cavity Cancers
  10. Phase 3 randomized study for evaluation of physician's choice treatment and triple metronomic as second-line therapy in head and neck cancer.
  11. Treatment pattern and outcomes of leptomeningeal carcinomatosis in India: CRSF201901 study.
  12. Treatment pattern post-osimertinib failure in EGFR mutated NSCLC in India-CRSF202002 study.
  13. Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients
  14. Tyrosine Kinase Inhibitor versus Physician Choice Chemotherapy in Second-Line Epidermal Growth Factor Receptor Mutation Non-Small Cell Lung Cancer: Post hoc Analysis of Randomized Control Trial
  15. Distress Management in Patients With Head and Neck Cancer Before Start of Palliative Chemotherapy: A Practical Approach
  16. Outcomes in Treatment-Naïve Patients With Metastatic Extremity Osteosarcoma Treated With OGS-12, a Novel Non–High-Dose Methotrexate–Based, Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center
  17. Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
  18. Table S1
  19. Table S3
  20. Supplementary Figure 1
  21. Table S2
  22. P2.03-027 Comparative Longitudinal Toxicity Analysis of EGFR Mutated NSCLC Treated with Either Pemetrexed Carboplatin or Gefitinib
  23. Development and validation of a predictive score, for identifying poor eastern cooperative oncology group performance status (performance status 3–4) advanced nonsmall cell lung cancer patients who are likely to benefit from tyrosine kinase inhibitors
  24. Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy
  25. Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
  26. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
  27. Drug-sensitive FGFR3 mutations in lung adenocarcinoma
  28. Supplementary Data
  29. P3.02b-007 Differential Efficacy of Gefitinib in Exon 19 or Exon 21 Mutated Adenocarcinoma Lung
  30. P3.02b-065 Third Line Therapy in EGFR Positive Advanced Non-Small Cell Lung Cancer
  31. P3.02b-090 Pemetrexed versus Gefitinib in EGFR Mutation Positive Lung Cancer: Results of a Phase 3 Study from India
  32. P3.02b-094 Rebiopsy Post Progression in EGFR Mutated Lung Cancer
  33. PUB118 Pre-Chemotherapy EGFR Mutation Status & Outcomes with Second Line Gefitinib in Advanced Adenocarcinoma Lung
  34. P3.02b-055 Impact of Pemetrexed Chemotherapy in Exon 19 or Exon 21 Mutated NSCLC
  35. P3.02b-058 Second-Line Therapy in EGFR Activating Mutation Positive Advanced NSCLC: Analysis from a Randomized Phase III First-Line Trial
  36. Chandrani et al. suppl Methods and Figures 20161110
  37. Chandrani et al. Supplementary Tables 20161110
  38. Expectations and preferences for palliative chemotherapy in head and neck cancers patients
  39. 386P Expectations and preferences for palliative chemotherapy in head and neck cancers patients
  40. 386P Expectations and preferences for palliative chemotherapy in head and neck cancers patients
  41. Weekly cisplatin (30–40 mg/m2) as radiosensitizer: Is it high or moderate emetic agent?
  42. Metronomic palliative chemotherapy in maxillary sinus tumor
  43. Efficacy of second‑line erlotinib in patients postprogression of first‑line chemotherapy in head and neck cancers
  44. Technically unresectable recurrent oral cancers: Is NACT the answer?
proceed to call

Share your details below, and we’ll reach out to you without delay.

Disclaimer : We will be using this information for calling purposes only.

SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct head and neck cancer case study using TCR-p53 therapy in inoperable squamous cell carcinoma
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male